11. 重症筋無力症 Myasthenia gravis Clinical trials / Disease details
臨床試験数 : 315 / 薬物数 : 232 - (DrugBank : 77) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04728425 (ClinicalTrials.gov) | August 28, 2020 | 14/7/2020 | Subcutaneous Immunoglobulin for Myasthenia Gravis | Efficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia Gravis | Myasthenia Gravis | Drug: subcutaneous immunoglobulin (SCIG);Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) | University Health Network, Toronto | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | Canada |
| 2 | NCT02100969 (ClinicalTrials.gov) | May 2015 | 27/3/2014 | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis | Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis | Myasthenia Gravis | Drug: HIZENTRA ® | Mazen Dimachkie, MD | CSL Behring | Completed | 18 Years | N/A | All | 23 | Phase 2 | United States;Canada |